IRL-201104 is under clinical development by Revolo Biotherapeutics and currently in Phase I for Food Allergy. According to GlobalData, Phase I drugs for Food Allergy have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IRL-201104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IRL-201104 is under development for the treatment of asthma, allergies, eosinophilic esophagitis, grass pollen allergy, seasonal allergic rhinitis, food allergy, coronavirus disease 2019 (COVID-19), coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome and ARDS Associated to Influenza Infection . The drug candidate is a peptide derived from mycobacterium tuberculosis chaperonin 60.1. It is administered through intravenous and subcutaneous routes.
It was also under development for dermatological indications.
Revolo Biotherapeutics overview
Revolo Biotherapeutics is developing first-in-class disease resetting therapeutics for inflammatory and immunological diseases. The company’s pipeline products including PIN201104 (1104) and IRL201805 (1805) are drug compounds derived from endogenous immunoregulatory proteins (mTB chaperonin and BiP) for the treatment of asthma and rheumatoid arthritis. It is developing novel immunomodulatory platforms that reset the immune system advancing the control and management of chronic inflammatory diseases facilitating disease modification and remission. Revolo Biotherapeutics is headquartered in Stevenage, Hertfordshire, the UK.
For a complete picture of IRL-201104’s drug-specific PTSR and LoA scores, buy the report here.